Zafodo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 19 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 41.39%
- Profit Growth 143.64%
- Ebitda 146.00%
- Net Worth 9.12%
- Total Assets 22.38%
About Zafodo Pharmaceuticals
Zafodo Pharmaceuticals Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 February 2006 and has a history of 19 years. Its registered office is in Palakkad, Kerala, India.
The Company is engaged in the Plastics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Ravisankar Maniyadath, Koduvayur Ramanathan, Koduvayur Viswanathan, and One other member serve as directors at the Company.
Company Details
- Location
Palakkad, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KL2006PTC019198
- Company No.
019198
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Zafodo Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravisankar Maniyadath  | Managing Director | 15-Feb-2006 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Koduvayur Ramanathan | Director | 15-Feb-2006 | Current |
| Koduvayur Viswanathan | Director | 15-Feb-2006 | Current |
| Koduvayur Ganesan | Director | 15-Feb-2006 | Current |
Financial Performance of Zafodo Pharmaceuticals.
Zafodo Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 41.39% increase. The company also saw a substantial improvement in profitability, with a 143.64% increase in profit. The company's net worth moved up by a moderate rise of 9.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zafodo Pharmaceuticals?
In 2016, Zafodo Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zafodo Pharmaceuticals?
Unlock and access historical data on people associated with Zafodo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zafodo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zafodo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
